Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tumors known as gliomas generally don’t respond to the immunotherapy drugs even when the tumor cells are “hypermutated."
One finding of the project was that, on average, the genome of cancer cells contains four or five “driver” mutations.
The crowd-sourced effort has yielded unexpected findings about angiosarcoma, a disease that’s been difficult to study because it is so rare.
In support of precision medicine, a new method enables scientists to separate cancer-driving mutations from passengers.
This finding could lead to very early cancer interventions.
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
New site-agnostic therapies highlight the importance of genetic testing.
Task force recommends BRCA screening for women at increased cancer risk
High-tech approach solves ‘real mystery’ in many cancers.
While most gene mutations are harmless, others are not and can spur the formation of cancer.
Dana-Farber researchers have shown that the mutated copy of the gene TP53 sabotages the normal, healthy copy.
First KRAS targeted therapy shows promise for lung and colon cancer
Both have tested positive for the BRCA2 gene mutation.
New study tests ability of natural language processing to search lung cancer patients’ records for treatable mutations.
Q&A: Riki Peters, PhD, MPH, on what this large genome-wide association study means for patients and the public
Tafinlar plus Mekinist shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.